Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 20/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 20/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18742560 | 0.97 | HDAC3 (0.61) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742727 | 0.94 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16266642 | 0.89 | HDAC3 (0.69) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742438 | 0.86 | HDAC3 (0.66) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742555 | 0.85 | HDAC6 (0.63) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18712282 | 0.84 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL20491383 | 0.83 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742534 | 0.83 | HDAC3 (0.65) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742638 | 0.83 | HDAC6 (0.61) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL25575773 | 0.81 | HDAC3 (0.80) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884850-B2 | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884850-B2 | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20170096413-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HDAC6 SELECTIVE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170096413-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HDAC6 SELECTIVE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2017-04-06 | — | — | US | disclosed |
| US-9464073-B2 | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464073-B2 | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors | ACETYLON PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150239869-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HDAC6 SELECTIVE INHIBITORS | ACETYLON PHARMACEUTICALS, INC. | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239869-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HDAC6 SELECTIVE INHIBITORS | HDAC6, HDAC1, HDAC5 | HDAC3 7/4885HDAC1 2/4885HDAC2 4/4885 |
| US-20170096413-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HDAC6 SELECTIVE INHIBITORS | HDAC6, HDAC1, HDAC5 | HDAC3 7/4885HDAC1 2/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.